Global Generic Drugs Market Analysis to 2026 - Vendors Covered Include Cipla, Novartis, Valeant & Baxter International Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Generic Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Generic Drugs market is expected to reach $738.56 billion by 2026 growing at a CAGR of 12.6% from 2018 to 2026.

Generic drugs are drugs with the chemical makeup of a drug equivalent to an existing branded drug. These drugs are cheaper and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application. Generic drugs are subjected to government regulations in various countries rather than being associated with a particular company.

Factors such as the increasing prevalence of chronic diseases, diabetes & cardiovascular diseases, growing healthcare expenditure, high demand for generic medicines, and a large number of patent expired branded drugs are driving the market growth. Though, high competition and the shortage of drugs are hampering the market growth.

Based on the therapy area, anti-infective drugs are agents that act against infections either by inhibiting the spread of an infectious agent or by destroying the infectious agent. Anti-infective drugs are required to destroy infectious agents that cause several infections in the human body such as tuberculosis, sepsis, and smallpox.

The key vendors mentioned are Cipla, Abbott Laboratories, Novartis International AG, Nichi-Iko Pharmaceutical, Mylan NV, Valeant, Hospira (Pfizer Inc.), Dr. Reddy's, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Fresenius Kabi Ag, Baxter International Inc., Actavis Pharmaceuticals, and Eli Lilly and Company.

Key Questions Answered in this Report:

• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analysed during the forecast period
  

Key Topics Covered:

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Generic Drugs Market, By Drug Delivery

5.1 Introduction

5.2 Dermal/Topical

5.3 Inhalers

5.4 Injectables

5.5 Oral

5.6 Parenteral

5.7 Other Drug Deliveries

6 Global Generic Drugs Market, By Brand

6.1 Introduction

6.2 Pure Generic Drugs

6.3 Branded Generic Drugs

7 Global Generic Drugs Market, By Therapy Area

7.1 Introduction

7.2 Dermatology

7.3 Diabetes

7.4 Respiratory Products

7.5 Rheumatology

7.6 Oncology

7.7 Genitourinary/Hormonal

7.8 Gastrointestinal Disorders

7.9 Pain Management

8 Global Generic Drugs Market, By Distribution Channel

8.1 Introduction

8.2 Retail Pharmacies

8.3 Drug Stores

8.4 Hospitals

8.5 Private Clinics

8.6 Online Pharmacies

9 Global Generic Drugs Market, By Therapeutic Drugs

9.1 Introduction

9.2 Cardiovascular Products

9.3 Anti-Infective Drugs

9.4 Anti-Arthritis Drugs

9.5 Central Nervous System Drugs

9.6 Anti-Cancer Drug

9.7 Antibiotics

10 Global Generic Drugs Market, By Category

10.1 Introduction

10.2 Bio-Similar

10.3 Small Molecule Generics

10.4 Super Generics

10.5 Simple Generics

11 Global Generic Drugs Market, By Geography

11.1 Introduction

11.2 North America

11.3 Europe

11.4 Asia Pacific

11.5 South America

11.6 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape

13.1 Cipla

13.2 Abbott Laboratories

13.3 Novartis International AG

13.4 Nichi-Iko Pharmaceutical

13.5 Mylan NV

13.6 Valeant

13.7 Hospira (Pfizer Inc.)

13.8 Dr. Reddy's

13.9 Sun Pharmaceutical Industries Ltd.

13.10 Teva Pharmaceutical Industries Ltd.

13.11 STADA Arzneimittel AG

13.12 Fresenius Kabi Ag

13.13 Baxter International Inc.

13.14 Actavis Pharmaceuticals

13.15 Eli Lilly and Company

For more information about this report visit https://www.researchandmarkets.com/r/2dlbvk